400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / Epigenetics / HDAC / Fimepinostat/非美诺司他
CAS No.: 1339928-25-4
Synonyms: CUDC-907;fimepinostat
CUDC-907 is a dual PI3K and HDAC inhibitor for PI3Kα and HDAC1/2/3/10 with IC50 of 19 nM and 1.7 nM/5 nM/1.8 nM/2.8 nM, respectively.
生物活性
靶点 | HDAC1 IC50:1.7nM | HDAC10 IC50:2.8nM | HDAC2 IC50:5nM | HDAC3 IC50:1.8nM | PI3Kα IC50:19nM |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT02913131 | Prostate Cancer | Phase 2 | Recruiting | April 2020 | United States, California ... more >> University of California, San Francisco Recruiting San Francisco, California, United States, 94158 Contact: Rahul Aggarwal, MD 877-827-3222 cancertrials@ucsf.edu Contact: Kamran Abri-Lavasani 877-827-3222 cancertrials@ucsf.edu Collapse << |
NCT01742988 | Multiple Myeloma ... more >> Lymphoma Collapse << | Phase 1 | Active, not recruiting | December 2018 | United States, California ... more >> USC/Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 United States, Florida Florida Cancer Specialists Sarasota, Florida, United States, 34232 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, Oklahoma Stephenson Cancer Center, University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma, United States, 73104 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT03002623 | Thyroid Neoplasms ... more >> Poorly Differentiated and Undifferentiated Thyroid Cancer Differentiated Thyroid Cancer Collapse << | Phase 2 | Completed | - | United States, Maryland ... more >> National Institutes of Health Clinical Center Bethesda, Maryland, United States, 20892 Collapse << |
实验方案
技术信息
CAS号 | 1339928-25-4 | 储存条件 |
|
|||||
分子式 | C23H24N8O4S | 运输 | 蓝冰 | |||||
分子量 | 508.55 | 别名 | CUDC-907;fimepinostat | |||||
溶解度 |
|
动物实验配方 |
Cell Lines | Concentration | Assay Type | Time | Activity Description | Data Sources |
---|
human Glioma cells (HF2303) | - | Cytotoxicity assay | 72 h | Cytotoxicity against human Glioma cells (HF2303) after 72 hrs by CelltiterGlo assay, EC50=0.7 nM | 26288699 |
human Glioma cells (HF2381) | - | Cytotoxicity assay | 72 h | Cytotoxicity against human Glioma cells (HF2381) after 72 hrs by CelltiterGlo assay, EC50=0.7 nM | 26288699 |
human Glioma cells (HF2476) | - | Cytotoxicity assay | 72 h | Cytotoxicity against human Glioma cells (HF2476) after 72 hrs by CelltiterGlo assay, EC50=0.7 nM | 26288699 |
human Glioma cells (HF2790) | - | Cytotoxicity assay | 72 h | Cytotoxicity against human Glioma cells (HF2790) after 72 hrs by CelltiterGlo assay, EC50=0.7 nM | 26288699 |
human Glioma cells (HF2876) | - | Cytotoxicity assay | 72 h | Cytotoxicity against human Glioma cells (HF2876) after 72 hrs by CelltiterGlo assay, EC50=0.7 nM | 26288699 |
human Glioma cells (HF2885) | - | Cytotoxicity assay | 72 h | Cytotoxicity against human Glioma cells (HF2885) after 72 hrs by CelltiterGlo assay, EC50=0.7 nM | 26288699 |
human Glioma cells (HF3013) | - | Cytotoxicity assay | 72 h | Cytotoxicity against human Glioma cells (HF3013) after 72 hrs by CelltiterGlo assay, EC50=0.7 nM | 26288699 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT02913131 | Prostate Cancer | Phase 2 | Recruiting | April 2020 | United States, California ... more >> University of California, San Francisco Recruiting San Francisco, California, United States, 94158 Contact: Rahul Aggarwal, MD 877-827-3222 cancertrials@ucsf.edu Contact: Kamran Abri-Lavasani 877-827-3222 cancertrials@ucsf.edu Collapse << |
NCT01742988 | Multiple Myeloma ... more >> Lymphoma Collapse << | Phase 1 | Active, not recruiting | December 2018 | United States, California ... more >> USC/Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 United States, Florida Florida Cancer Specialists Sarasota, Florida, United States, 34232 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, Oklahoma Stephenson Cancer Center, University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma, United States, 73104 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT03002623 | Thyroid Neoplasms ... more >> Poorly Differentiated and Undifferentiated Thyroid Cancer Differentiated Thyroid Cancer Collapse << | Phase 2 | Completed | - | United States, Maryland ... more >> National Institutes of Health Clinical Center Bethesda, Maryland, United States, 20892 Collapse << |
NCT02674750 | Relapsed and/or Refractory Dif... more >>fuse Large B-cell Lymphoma Including With Myc Alterations Collapse << | Phase 2 | Recruiting | - | - |
NCT02307240 | Triple-Negative Breast Cancer ... more >> High-grade Serous Ovarian Cancer Solid Tumors NUT Midline Carcinoma Collapse << | Phase 1 | Recruiting | December 2018 | United States, California ... more >> UCSF School of Medicine Recruiting San Francisco, California, United States, 94143 United States, Florida Florida Cancer Specialists Recruiting Sarasota, Florida, United States, 34232 United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 United States, Texas The University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Collapse << |
NCT02909777 | Lymphoma Neur... more >>oblastoma Brain Tumor Solid Tumor Collapse << | Phase 1 | Recruiting | October 2022 | United States, California ... more >> University of California, San Francisco, Benioff Children's Hospital Recruiting San Francisco, California, United States, 94158 Contact: Kieuhoa Vo, MD 415-476-3831 kieuhoa.vo@ucsf.edu Principal Investigator: Kieuhoa Vo, MD United States, Massachusetts Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 Contact: Steven DuBois, MD, MS 617-632-5460 steven_dubois@dfci.harvard.edu Principal Investigator: Steven DuBois, MD, MS United States, Pennsylvania Children's Hospital of Philadelphia Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Elizabeth Fox, MD 267-425-3010 foxe@email.chop.edu Principal Investigator: Elizabeth Fox, MD United States, Texas Texas Children's, Baylor College of Medicine Recruiting Houston, Texas, United States, 77030 Contact: Jodi Muscal, MD 832-824-4632 jamuscal@txch.org Principal Investigator: Jodi Muscal, MD Collapse << |
靶点 | Description | IC50 |
---|---|---|
HDAC1 | IC50:1.7nM | |
HDAC10 | IC50:2.8nM | |
HDAC2 | IC50:5nM | |
HDAC3 | IC50:1.8nM | |
PI3Kα | IC50:19nM |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网